Bolt Biotherapeutics, Inc.
BOLT
Rank in Stocks
#28102
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting... Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Share Price
$6.43
Last synced: 2026-11-09
Market Cap
$12.39M
Change (1 day)
-1.68%
Change (1 year)
33.68%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Bolt Biotherapeutics, Inc. (BOLT)
Category
Healthcare
EPS for Bolt Biotherapeutics, Inc. (BOLT)
EPS as of June 2026 TTM: $-16.00
According to Bolt Biotherapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-16.00. At the end of 2025 the company had an EPS of $-17.85, a decrease compared to its 2024 EPS of $-1.65.
EPS history for Bolt Biotherapeutics, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-16.00 | -10.36% |
| 2025 | $-17.85 | 981.82% |
| 2024 | $-1.65 | -9.84% |
| 2023 | $-1.83 | -20.43% |
| 2022 | $-2.30 | -17.56% |
| 2021 | $-2.79 | 40.20% |
| 2020 | $-1.99 | -46.93% |
| 2019 | $-3.75 | -37.08% |
| 2018 | $-5.96 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -197.88% |
US
|
|
| $-7.07 | -55.81% |
US
|
|
| $-5.29 | -66.94% |
AU
|
|
| $12.88 | -180.50% |
BE
|
|
| $21.56 | -234.75% |
NL
|
Questions about Bolt Biotherapeutics, Inc.'s earnings per share (EPS)
What is Bolt Biotherapeutics, Inc.'s earnings per share (EPS)?
Bolt Biotherapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-16.00, as of Jun 2026.
What was Bolt Biotherapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Bolt Biotherapeutics, Inc.'s earnings per share (EPS) was $-17.85, compared with $-1.65 in 2024.
How has Bolt Biotherapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Bolt Biotherapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-1.65) and lowest in 2025 ($-17.85).
How does Bolt Biotherapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Bolt Biotherapeutics, Inc.'s earnings per share (EPS) ($-16.00) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.